Clinical trials: Colorectal Tumors
Non-small Cell Lung Cancer, Colorectal Cancer
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid…
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT05935384
- Testing
- Guardant360
- Where
- United States
- Volunteers
- 470 people
- Sponsor
- Guardant Health, Inc.
Colorectal Cancer, Polyp, Colonic
Technical Feasibility Evaluation of Mucosal Staining During Colon Capsule Endoscopy (CCE) Procedure in Colorectal Cancer (CRC) High Risk Population, When Using MB-MMX
A prospective, single-center, single-arm, non-randomized, post-market pilot study evaluating the technical feasibility of mucosal staining during COLON2 Capsule Endoscopy (CCE) procedure in population at high risk for Colorectal…
- Trial name
- NCT05022719
- Testing
- PillCam Colon2 procedure with MB-MMX
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Medtronic - MITG
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies.
- Trial name
- HERKULES-3 (NCT05039177)
- Testing
- ERAS-007, Encorafenib, Cetuximab
- Where
- 14 sites in United States
- Volunteers
- 101 people
- Sponsor
- Erasca, Inc.
Colorectal Cancer
An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer
This observational study will evaluate the efficacy and safety of different capecitabine based chemotherapies, alone or in combination with other therapies, as first line treatment of metastatic colorectal cancer in participants…
- Trial name
- AXEL (NCT01696695)
- Testing
- Capecitabine, Chemotherapy
- Where
- 22 sites in Hungary
- Volunteers
- 882 people
- Sponsor
- Hoffmann-La Roche
Rectal Cancer, Colon Cancer
Perfusion Assessment in Laparoscopic Left Anterior Resection
The purpose of this study is to demonstrate that NIR fluorescence angiography using the PINPOINT Endoscopic Fluorescence Imaging System ("PINPOINT System" or "PINPOINT") can assess viability of colon tissue during laparoscopic…
- Conditions
- Rectal Cancer, Colon Cancer, Crohn's Disease, Polyp
- Trial name
- PILLAR II (NCT01560377)
- Testing
- PINPOINT Endoscopic Fluorescence Imaging System
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Metastatic Colorectal Cancer
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
This study is designed to evaluate the mechanism(s) of resistance to the anti-epidermal growth factor receptor (EGFR) antibody panitumumab given in combination with irinotecan in metastatic colorectal carcinoma (mCRC) patients…
- Trial name
- NCT00891930
- Testing
- Panitumumab, Ganitumab, Irinotecan
- Volunteers
- 74 people
- Sponsor
- NantBioScience, Inc.
Colorectal Cancer
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and how telisotuzumab adizutecan moves through the body of adult participants…
- Trial name
- NCT06464692
- Testing
- Telisotuzumab Adizutecan
- Where
- 8 sites in China
- Volunteers
- 31 people
- Sponsor
- AbbVie
Colorectal Cancer
A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study will evaluate the efficacy and safety of adding bevacizumab to crossover fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer who have experienced disease progression under first line…
- Trial name
- NCT00700102
- Testing
- Chemotherapy, Bevacizumab
- Where
- 300 sites in Austria, Belgium and 13 more
- Volunteers
- 820 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab…
- Trial name
- NCT02671435
- Testing
- Monalizumab, Durvalumab, Cetuximab
- Where
- 49 sites in United States, Australia and 9 more
- Volunteers
- 383 people
- Sponsor
- MedImmune LLC
Gastric Cancer, Non-small Cell Lung Cancer
Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers
Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist.
- Conditions
- Gastric Cancer, Non-small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05800418
- Testing
- Ramucirumab Injection, Ramucirumab Injection [Cyramza]
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Unresectable Metastatic Colorectal Cancer
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with…
- Trial name
- NCT06107413
- Testing
- ABBV-400, Bevacizumab, Folinic Acid
- Where
- 64 sites in United States, Belgium and 6 more
- Volunteers
- 280 people
- Sponsor
- AbbVie
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Colorectal Cancer
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
The trial will compare the overall survival of perifosine plus capecitabine to placebo plus capecitabine in patients with refractory advanced colorectal cancer.
- Trial name
- X-PECT (NCT01097018)
- Testing
- Capecitabine, Perifosine
- Where
- 65 sites in United States
- Volunteers
- 468 people
- Sponsor
- AEterna Zentaris
Neoplasms, Non-small-cell Lung Cancer
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or…
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT06285097
- Testing
- PF-07820435, Sasanlimab
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 9 people
- Sponsor
- Pfizer
Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of STC-1010 associated with GM-CSF and cyclophosphamide immunostimulant…
- Trial name
- NCT06934538
- Testing
- STC-1010 + IS regimen + SOC therapy
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 90 people
- Sponsor
- Brenus Pharma
Colorectal Cancer
Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing
In order for flexible sigmoidoscopy to be a successful screening procedure, the bowel must be free of solid matter so the endoscopist has a clear view, increasing the chance of detection of abnormalities.
- Trial name
- NCT02468726
- Testing
- NER1008 enema, Fleet
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Norgine
Cancer, Neoplasms
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Conditions
- Cancer, Neoplasms, Neoplasms, Breast, Tumor
- Trial name
- NCT06819215
- Testing
- VB15010
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Clear Cell Renal Cell Carcinoma
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum…
- Trial name
- NCT05433142
- Testing
- XmAb819
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 307 people
- Sponsor
- Xencor, Inc.
Breast Cancer, Ovarian Cancer
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
This is a randomized Phase 1 study to evaluate the effects of Veliparib on cardiac repolarization in patients with solid tumors who's cancer has recurred or is no longer responding to current treatment.
- Conditions
- Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer
- Trial name
- NCT02009631
- Testing
- Veliparib (ABT-888)
- Where
- 5 sites in United States, Netherlands and 1 more
- Volunteers
- 45 people
- Sponsor
- AbbVie
Colorectal Carcinoma
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease to irinotecan-based chemotherapy and who have…
- Trial name
- NCT00362102
- Testing
- Cetuximab
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.